Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement only “as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.”
Unfavourable opinion for reimbursement in the other situations covered by the MA indication.
Clinical Benefit
| Substantial |
The clinical benefit of RYSTIGGO (rozanolixizumab) is substantial only as an add-on to standard therapy, including first-line immunosuppressants, for the treatment of generalised myasthenia gravis (gMG) in adultpatients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive, who remain symptomatic.
|
See also
HAS opinions and decisions
03/05/2024
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
WBpwg8hKQsPhBUYw
